1146 related articles for article (PubMed ID: 33160824)
1. Sphingolipids metabolism alteration in the central nervous system: Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Bouscary A; Quessada C; René F; Spedding M; Turner BJ; Henriques A; Ngo ST; Loeffler JP
Semin Cell Dev Biol; 2021 Apr; 112():82-91. PubMed ID: 33160824
[TBL] [Abstract][Full Text] [Related]
2. The role of lipids in the central nervous system and their pathological implications in amyotrophic lateral sclerosis.
Tracey TJ; Kirk SE; Steyn FJ; Ngo ST
Semin Cell Dev Biol; 2021 Apr; 112():69-81. PubMed ID: 32962914
[TBL] [Abstract][Full Text] [Related]
3. Microglial TREM2 in amyotrophic lateral sclerosis.
Xie M; Zhao S; Bosco DB; Nguyen A; Wu LJ
Dev Neurobiol; 2022 Jan; 82(1):125-137. PubMed ID: 34874625
[TBL] [Abstract][Full Text] [Related]
4. Protein misfolding in the late-onset neurodegenerative diseases: common themes and the unique case of amyotrophic lateral sclerosis.
Mulligan VK; Chakrabartty A
Proteins; 2013 Aug; 81(8):1285-303. PubMed ID: 23508986
[TBL] [Abstract][Full Text] [Related]
5. [The role of sphingolipids in pathogenesis of amyotrophic lateral sclerosis].
Alessenko AV; Gutner UA; Nebogatikov VO; Shupik MA; Ustyugov AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):131-140. PubMed ID: 34481449
[TBL] [Abstract][Full Text] [Related]
6. Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases.
Bouscary A; Quessada C; René F; Spedding M; Henriques A; Ngo S; Loeffler JP
Eur J Pharmacol; 2020 Oct; 884():173446. PubMed ID: 32739173
[TBL] [Abstract][Full Text] [Related]
7. SIRT3 and mitochondrial metabolism in neurodegenerative diseases.
Salvatori I; Valle C; Ferri A; Carrì MT
Neurochem Int; 2017 Oct; 109():184-192. PubMed ID: 28449871
[TBL] [Abstract][Full Text] [Related]
8. Exploring Sphingolipid Implications in Neurodegeneration.
Alessenko AV; Albi E
Front Neurol; 2020; 11():437. PubMed ID: 32528400
[TBL] [Abstract][Full Text] [Related]
9. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase.
Henriques A; Croixmarie V; Priestman DA; Rosenbohm A; Dirrig-Grosch S; D'Ambra E; Huebecker M; Hussain G; Boursier-Neyret C; Echaniz-Laguna A; Ludolph AC; Platt FM; Walther B; Spedding M; Loeffler JP; Gonzalez De Aguilar JL
Hum Mol Genet; 2015 Dec; 24(25):7390-405. PubMed ID: 26483191
[TBL] [Abstract][Full Text] [Related]
10. Ceramide and Sphingosine-1-Phosphate in Neurodegenerative Disorders and Their Potential Involvement in Therapy.
Tringali C; Giussani P
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887154
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis.
Richardson PJ; Smith DP; de Giorgio A; Snetkov X; Almond-Thynne J; Cronin S; Mead RJ; McDermott CJ; Shaw PJ
Transl Neurodegener; 2023 Oct; 12(1):47. PubMed ID: 37828541
[TBL] [Abstract][Full Text] [Related]
12. Axonal transport and neurodegenerative disease.
Chevalier-Larsen E; Holzbaur EL
Biochim Biophys Acta; 2006; 1762(11-12):1094-108. PubMed ID: 16730956
[TBL] [Abstract][Full Text] [Related]
13. Examining the relationship between astrocyte dysfunction and neurodegeneration in ALS using hiPSCs.
Halpern M; Brennand KJ; Gregory J
Neurobiol Dis; 2019 Dec; 132():104562. PubMed ID: 31381978
[TBL] [Abstract][Full Text] [Related]
14. Evidence for alterations in lipid profiles and biophysical properties of lipid rafts from spinal cord in sporadic amyotrophic lateral sclerosis.
Díaz M; Fabelo N; Martín MV; Santos G; Ferrer I
J Mol Med (Berl); 2024 Mar; 102(3):391-402. PubMed ID: 38285093
[TBL] [Abstract][Full Text] [Related]
15. [The role of lipids in the pathogenesis of lateral amyotrophic sclerosis].
Alessenko AV; Gutner UA; Nebogatikov VO; Shupik MA; Ustyugov AA
Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(10):108-117. PubMed ID: 33244966
[TBL] [Abstract][Full Text] [Related]
16. Molecular basis of amyotrophic lateral sclerosis.
Liscic RM; Breljak D
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):370-2. PubMed ID: 20655970
[TBL] [Abstract][Full Text] [Related]
17. Neurodegenerative Disorders: Spotlight on Sphingolipids.
Mandik F; Vos M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769423
[TBL] [Abstract][Full Text] [Related]
18. Proteostasis impairment and ALS.
Lambert-Smith IA; Saunders DN; Yerbury JJ
Prog Biophys Mol Biol; 2022 Oct; 174():3-27. PubMed ID: 35716729
[TBL] [Abstract][Full Text] [Related]
19. Stem Cells: Innovative Therapeutic Options for Neurodegenerative Diseases?
Bonaventura G; Munafò A; Bellanca CM; La Cognata V; Iemmolo R; Attaguile GA; Di Mauro R; Di Benedetto G; Cantarella G; Barcellona ML; Cavallaro S; Bernardini R
Cells; 2021 Aug; 10(8):. PubMed ID: 34440761
[TBL] [Abstract][Full Text] [Related]
20. Senolytics: A Novel Strategy for Neuroprotection in ALS?
Maximova A; Werry EL; Kassiou M
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
